Verastem Oncology
@VerastemOncolog
Followers
3K
Following
2K
Statuses
1K
Verastem Oncology is committed to developing and commercializing medicines to improve the lives of patients with #RAS/MAPK-driven #cancers. $VSTM
Needham, MA
Joined January 2018
On February 5th, we’ll be participating in the Guggenheim SMID Cap Biotech Conference. A live webcast of our session will be available on our website. $VSTM
0
0
5
Today, we shared our 2025 outline of strategic priorities and milestones for our novel pipeline, with hopes to advance new medicines for patients with RAS/MAPK pathway-driven cancers. $VSTM
0
0
9
Today, we announced a new credit facility and equity investment with Oberland Capital and a strategic commercialization collaboration with @IQVIA_Global $VSTM #LGSOC
0
0
0
The FDA has accepted and granted Priority Review to our NDA for our investigational combination of avutometinib and defactinib for the treatment of recurrent KRAS mutant Low-Grade Serous Ovarian Cancer. Read more: $VSTM #LGSOC
0
3
11
Update on our RAMP 203 trial with Amgen: We're evaluating investigational combo of avutometinib + sotorasib +/- defactinib in KRAS G12C mutant NSCLC. Preliminary data on the triplet combo looks encouraging. We look forward to sharing more at a medical meeting in 2H 2025. $VSTM
0
0
6
Next week we will be participating in a fireside chat at the 7th Annual @EvercoreISI HealthCONx Conference on Dec. 3rd. A live webcast of our chat will be available on our website. Learn more: $VSTM
0
0
1
With more than 90% of #pancreaticcancers harboring a KRAS mutation, we’re researching innovative ways to target the RAS/MAPK-pathway and other resistance mechanisms to improve outcomes for patients with pancreatic cancer. #WorldPancreaticCancerDay #WPCD #WPCD2024
0
1
4
Today, we’re reporting our Q3 financial results and recent business progress, including completing our rolling NDA submission of our investigational combination of avutometinib plus defactinib for patients with recurrent KRAS mutant LGSOC. $VSTM
0
0
3
We have completed our rolling NDA to the U.S. FDA for the investigational and potential first-in-class combination of avutometinib plus defactinib for recurrent KRAS mutant LGSOC. $VSTM #LGSOC
0
1
6
The RAMP 201 study in recurrent #LGSOC, is one of the largest studies ever conducted in this rare #ovariancancer. Later today, we will share detailed findings at the @IGCSociety Annual Meeting. #IGCS2024
0
0
7
Today, we announced positive updated RAMP 201 data for our investigational combination being evaluated in recurrent #LGSOC. These data are being presented at the @IGCSociety meeting later today. #IGCS2024. $VSTM #OvarianCancer
0
0
8
Going to @IGCSociety meeting in Dublin? Visit Verastem at Booth #22 to learn more about our clinical research in the RAS/MAPK pathway. #IGSC2024 #KRAS #gynonc $VSTM
0
1
5
Today for World Mental Health Day we’re elevating how a diagnosis of LGSOC, can take a toll on the mental health and quality of life of people diagnosed with this cancer and their families #WorldMentalHealthDay #LGSOC #cancermentalhealth
0
0
1
Today, we announced the details for the oral presentation of the late-breaking abstract of mature RAMP 201 data at the @IGCSociety 2024 annual meeting. #IGSC2024 #KRAS #RAS #LGSOC
0
0
8
RT @NOCC_National: At 38, Rachel P. was diagnosed with Stage 3A low-grade serous ovarian cancer in 2020. Today, she pays it forward by dist…
0
3
0
Today at the RAS-Targeted Drug Discovery and Development Summit we will share an overview of the #RAS targeting space as well as a few of our own approaches in targeting RAS/MAPK pathway driven cancers. #cancerresearch
0
0
4
This weekend we will be lacing up our shoes for the @NOCC_National Together In Teal walk in Boston to end #ovariancancer. It’s not too late to join us! #LGSOC #OvarianCancerAwarenessMonth #KnowOvarian
0
0
4
This past weekend, we presented at the @PanCan Scientific Summit in Boston to provide an overview of our ongoing RAMP 205 study in 1L metastatic #pancreaticcancer and progress with the RAF/MEK translational science working group. #pancsm
0
1
6